Avecia
| Formerly | Avecia Biotechnology Inc. (2001–2012) |
|---|---|
| Company type | Subsidiary |
| Industry | Biotechnology |
| Defunct | 15 September 2015  |
| Headquarters | Milford, Massachusetts, U.S. |
| Parent | Nitto Denko Corporation |
Avecia, a part of Nitto Denko Inc., is a private biotechnology company focused on oligonucleotide production.[1] Avecia has two facilities, one near Boston, MA, and the second in Cincinnati, OH.[1] In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals.[2] Avecia was organized with a biologics business line and the oligonucleotide business line. In 2009, Avecia Biologics Limited based in Billingham, UK was acquired by Merck and was later part of Fujifilm Diosynth Biotechnologies.[3]
References
- ^ a b Kansteiner, Fraiser (March 31, 2021). "Nitto Denko lays out $226M to boost oligonucleotide production in a bustling RNA market". Fierce Pharma. Retrieved June 3, 2024.
- ^ "Nitto Denko Avecia Inc acquires businesses of Irvine Pharmaceutical Services, Avrio Biopharmaceuticals". Reuters. October 11, 2016. Retrieved June 3, 2024.
- ^ "Merck & Co., Inc. to Acquire Avecia Biologics | Fierce Biotech". www.fiercebiotech.com. 17 December 2009.